Photo by nci from unsplash
The development of neutralizing antibodies (inhibitors) against coagulation factor VIII (FVIII) is currently the most serious complication for patients with haemophilia A undergoing FVIII replacement therapy. Several genetic factors have… Click to show full abstract
The development of neutralizing antibodies (inhibitors) against coagulation factor VIII (FVIII) is currently the most serious complication for patients with haemophilia A undergoing FVIII replacement therapy. Several genetic factors have been acknowledged as risk factors for inhibitor development.
Keywords:
antibodies brothers;
factor viii;
viii antibodies;
factor;
anti factor
Journal Title: Haemophilia
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Haemophilia
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!